10.6084/m9.figshare.5633911 Viviane Gresset-Bourgeois Viviane Gresset-Bourgeois Phillip S. Leventhal Phillip S. Leventhal Stéphanie Pepin Stéphanie Pepin Rosalind Hollingsworth Rosalind Hollingsworth Marie-Pierre Kazek-Duret Marie-Pierre Kazek-Duret Iris De Bruijn Iris De Bruijn Sandrine I. Samson Sandrine I. Samson Quadrivalent inactivated influenza vaccine (VaxigripTetra™) Taylor & Francis Group 2017 Clinical trial immunogenicity inactivated influenza vaccine influenza B quadrivalent influenza vaccine safety 2017-11-27 12:12:25 Journal contribution https://tandf.figshare.com/articles/journal_contribution/Quadrivalent_inactivated_influenza_vaccine_VaxigripTetra_/5633911 <p><b>Introduction</b>: VaxigripTetra™ (IIV4; Sanofi Pasteur) is a quadrivalent split-virion influenza vaccine approved in Europe in 2016 for individuals ≥ 3 years of age. IIV4 builds on the well-established record of the trivalent split-virion influenza vaccine (Vaxigrip®).</p> <p><b>Areas covered</b>: This literature review summarizes the rationale for developing quadrivalent influenza vaccines and discusses the phase III clinical trial results supporting the immunogenicity, safety, and tolerability of IIV4.</p> <p><b>Expert commentary</b>: IIV4 is immunogenic and well tolerated. Adding a second B strain to the trivalent split-virion influenza vaccine provides a superior immune response for the additional strain but does not reduce the immune response for the three other strains or negatively affect the safety profile. By offering broader protection against co-circulating influenza B lineages, IIV4 has the potential to further reduce influenza-related morbidity and mortality beyond that achieved with trivalent vaccines.</p>